Photocure
26
2
2
19
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
15.4%
4 terminated/withdrawn out of 26 trials
82.6%
-3.9% vs industry average
23%
6 trials in Phase 3/4
63%
12 of 19 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (26)
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
Role: lead
Blue Light Cystoscopy With Cysview® Registry
Role: lead
Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer
Role: lead
The Impact of PDD During TURB for NMIBC
Role: collaborator
RESECT: Improving Quality in TURBT Surgery.
Role: collaborator
Treatment of Female Genital Erosive Lichen Planus(GELP) With Hexaminolevulinate PDT
Role: collaborator
Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB
Role: lead
A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting
Role: lead
Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia
Role: lead
Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients
Role: lead
A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris
Role: lead
Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)
Role: lead
Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer
Role: lead
An Open Dose-finding Study of Oral Applied Hexaminolevulinate (HAL) Imaging in Patients With Suspicion or High Risk of Neoplasia in the Colon
Role: lead
Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy
Role: lead
A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer
Role: lead
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne
Role: lead
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
Role: lead
Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1
Role: lead
Detection of Bladder Tumors After 30 Min Instillation of Hexvix
Role: lead